Deepull's €50 Million Series C: A Game Changer in Sepsis Diagnostics
May 2, 2025, 9:37 pm
deepull.com
Total raised: $69.62M
In the world of medical diagnostics, speed is life. Every second counts, especially when it comes to sepsis—a condition that claims lives at an alarming rate. Enter deepull, a Barcelona-based company that has just secured €50 million in an oversubscribed Series C financing round. This funding is not just a financial boost; it’s a lifeline for patients and healthcare providers alike.
Deepull is on a mission to revolutionize how we diagnose sepsis. The company’s flagship product, the UllCORE diagnostic system, is designed to detect pathogens directly from blood samples. This technology is a beacon of hope in a field where traditional methods often lag behind the urgency of patient needs.
The Series C round was co-led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. Existing investors, including Asabys Partners and We Venture Capital, also joined the fray, underscoring the confidence in deepull’s vision. The oversubscription of this round speaks volumes about the potential investors see in the company’s technology.
Sepsis is a silent killer. It accounts for one in three hospital deaths in the U.S. and has a global mortality rate of 30-40%. The symptoms can be vague, making early diagnosis a daunting challenge. Current diagnostic methods rely on blood cultures that can take days to yield results. In a race against time, this delay can be fatal.
Deepull’s UllCORE system is a game changer. It employs cutting-edge molecular techniques to extract and detect microbial DNA from whole blood. This fully automated, walkaway system can deliver critical results in about one hour. It targets 95% of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes. In a world where every minute matters, this rapid response could save countless lives.
The funds from the Series C financing will be used to finalize clinical validation and expedite the regulatory approval process for UllCORE. The system has already received Breakthrough Device Designation from the U.S. Food and Drug Administration, a significant milestone that highlights its potential impact on patient care.
Deepull’s CEO, Jordi Carrera, emphasized the importance of this funding. It marks a critical step toward completing clinical studies and bringing their transformative diagnostic solution to market. The support from investors reflects a growing recognition of the urgent need for better diagnostic tools in the fight against sepsis.
The healthcare landscape is evolving. Investors are increasingly looking for solutions that not only promise returns but also have the potential to make a real difference in patient outcomes. Deepull fits this mold perfectly. The company’s technology addresses a pressing need in the medical community, making it an attractive option for investors who want to be part of something meaningful.
The UllCORE system is not just another diagnostic tool; it’s a lifeline for healthcare providers. In emergency situations, the ability to quickly identify pathogens can lead to timely and appropriate treatment. This is crucial in managing sepsis, where every moment counts. The faster a diagnosis is made, the sooner treatment can begin, potentially reducing mortality rates significantly.
The implications of deepull’s technology extend beyond just sepsis. The ability to rapidly detect pathogens from blood samples could revolutionize how acute infections are diagnosed and treated. This could lead to better patient outcomes across a range of conditions, making deepull a key player in the future of medical diagnostics.
As deepull prepares to move forward, the excitement in the air is palpable. The company is poised to redefine diagnostic standards, and the backing from prominent investors is a testament to its potential. The journey from concept to commercialization is fraught with challenges, but deepull is ready to tackle them head-on.
In a world where medical advancements can mean the difference between life and death, deepull stands at the forefront. The €50 million raised in this Series C round is not just capital; it’s a commitment to innovation, a promise to patients, and a step toward a future where sepsis can be diagnosed swiftly and accurately.
The road ahead is filled with possibilities. With the right support and continued innovation, deepull could very well change the landscape of medical diagnostics. The fight against sepsis is far from over, but with tools like UllCORE, there’s hope on the horizon.
In conclusion, deepull’s recent funding round is a significant milestone in the battle against sepsis. The company’s innovative approach to diagnostics could save lives and transform patient care. As they move closer to commercialization, the medical community watches with bated breath. The future of sepsis diagnosis is bright, and deepull is leading the charge.
Deepull is on a mission to revolutionize how we diagnose sepsis. The company’s flagship product, the UllCORE diagnostic system, is designed to detect pathogens directly from blood samples. This technology is a beacon of hope in a field where traditional methods often lag behind the urgency of patient needs.
The Series C round was co-led by Columbus Venture Partners, Panakès Partners, and Mérieux Equity Partners. Existing investors, including Asabys Partners and We Venture Capital, also joined the fray, underscoring the confidence in deepull’s vision. The oversubscription of this round speaks volumes about the potential investors see in the company’s technology.
Sepsis is a silent killer. It accounts for one in three hospital deaths in the U.S. and has a global mortality rate of 30-40%. The symptoms can be vague, making early diagnosis a daunting challenge. Current diagnostic methods rely on blood cultures that can take days to yield results. In a race against time, this delay can be fatal.
Deepull’s UllCORE system is a game changer. It employs cutting-edge molecular techniques to extract and detect microbial DNA from whole blood. This fully automated, walkaway system can deliver critical results in about one hour. It targets 95% of sepsis-causing pathogens, including bacteria and fungi, as well as antibiotic resistance genes. In a world where every minute matters, this rapid response could save countless lives.
The funds from the Series C financing will be used to finalize clinical validation and expedite the regulatory approval process for UllCORE. The system has already received Breakthrough Device Designation from the U.S. Food and Drug Administration, a significant milestone that highlights its potential impact on patient care.
Deepull’s CEO, Jordi Carrera, emphasized the importance of this funding. It marks a critical step toward completing clinical studies and bringing their transformative diagnostic solution to market. The support from investors reflects a growing recognition of the urgent need for better diagnostic tools in the fight against sepsis.
The healthcare landscape is evolving. Investors are increasingly looking for solutions that not only promise returns but also have the potential to make a real difference in patient outcomes. Deepull fits this mold perfectly. The company’s technology addresses a pressing need in the medical community, making it an attractive option for investors who want to be part of something meaningful.
The UllCORE system is not just another diagnostic tool; it’s a lifeline for healthcare providers. In emergency situations, the ability to quickly identify pathogens can lead to timely and appropriate treatment. This is crucial in managing sepsis, where every moment counts. The faster a diagnosis is made, the sooner treatment can begin, potentially reducing mortality rates significantly.
The implications of deepull’s technology extend beyond just sepsis. The ability to rapidly detect pathogens from blood samples could revolutionize how acute infections are diagnosed and treated. This could lead to better patient outcomes across a range of conditions, making deepull a key player in the future of medical diagnostics.
As deepull prepares to move forward, the excitement in the air is palpable. The company is poised to redefine diagnostic standards, and the backing from prominent investors is a testament to its potential. The journey from concept to commercialization is fraught with challenges, but deepull is ready to tackle them head-on.
In a world where medical advancements can mean the difference between life and death, deepull stands at the forefront. The €50 million raised in this Series C round is not just capital; it’s a commitment to innovation, a promise to patients, and a step toward a future where sepsis can be diagnosed swiftly and accurately.
The road ahead is filled with possibilities. With the right support and continued innovation, deepull could very well change the landscape of medical diagnostics. The fight against sepsis is far from over, but with tools like UllCORE, there’s hope on the horizon.
In conclusion, deepull’s recent funding round is a significant milestone in the battle against sepsis. The company’s innovative approach to diagnostics could save lives and transform patient care. As they move closer to commercialization, the medical community watches with bated breath. The future of sepsis diagnosis is bright, and deepull is leading the charge.